No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes

This publication has 35 references indexed in Scilit:

• Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations inPCSK9
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2004
• Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice
  Journal of Lipid Research, 2003
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
  Nature Genetics, 2003
• Locus on Chromosome 6p Linked to Elevated HDL Cholesterol Serum Levels and to Protection Against Premature Atherosclerosis in a Kindred With Familial Hypercholesterolemia
  Circulation Research, 2003
• The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation
  Proceedings of the National Academy of Sciences, 2003
• The molecular basis of familial hypercholesterolemia in The Netherlands
  Human Genetics, 2001
• Results from a family and DNA based active identification programme for familial hypercholesterolaemia
  Journal of Epidemiology and Community Health, 2001
• The Molecular Mechanism for the Genetic Disorder Familial Defective Apolipoprotein B100
  Journal of Biological Chemistry, 2001
• Independent Mutations at Codon 3500 of the Apolipoprotein B Gene Are Associated With Hyperlipidemia
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity.
  Journal of Clinical Investigation, 1995